BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Rosen LS. VEGF-targeted therapy: therapeutic potential and recent advances. Oncologist. 2005;10:382-391. [PMID: 15967832 DOI: 10.1634/theoncologist.10-6-382] [Cited by in Crossref: 93] [Cited by in F6Publishing: 89] [Article Influence: 5.5] [Reference Citation Analysis]
Number Citing Articles
1 Morgan MA, Reuter CWM. Molecularly targeted therapies in myelodysplastic syndromes and acute myeloid leukemias. Ann Hematol 2006;85:139-63. [DOI: 10.1007/s00277-005-0051-7] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 1.5] [Reference Citation Analysis]
2 Das A, Mahapatra S, Bandyopadhyay D, Samanta S, Chakraborty S, Philpotts LL, Jahangir E, Roy B. Bleeding with vascular endothelial growth factor tyrosine kinase inhibitor: A network meta-analysis. Crit Rev Oncol Hematol 2021;157:103186. [PMID: 33309571 DOI: 10.1016/j.critrevonc.2020.103186] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
3 Zhu Z, Ying Z, Zeng M, Zhang Q, Liao G, Liang Y, Li C, Zhang C, Wang X, Jiang W, Luan P, Sha O. Trichosanthin cooperates with Granzyme B to restrain tumor formation in tongue squamous cell carcinoma. BMC Complement Med Ther 2021;21:88. [PMID: 33750370 DOI: 10.1186/s12906-021-03266-6] [Reference Citation Analysis]
4 Burstein HJ, Elias AD, Rugo HS, Cobleigh MA, Wolff AC, Eisenberg PD, Lehman M, Adams BJ, Bello CL, Deprimo SE, Baum CM, Miller KD. Phase II Study of Sunitinib Malate, an Oral Multitargeted Tyrosine Kinase Inhibitor, in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane. JCO 2008;26:1810-6. [DOI: 10.1200/jco.2007.14.5375] [Cited by in Crossref: 369] [Cited by in F6Publishing: 169] [Article Influence: 26.4] [Reference Citation Analysis]
5 Abdi S, Montazeri V, Garjani A, Shayanfar A, Pirouzpanah S. Coenzyme Q10 in association with metabolism-related AMPK/PFKFB3 and angiogenic VEGF/VEGFR2 genes in breast cancer patients. Mol Biol Rep 2020;47:2459-73. [DOI: 10.1007/s11033-020-05310-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
6 Kaya M, Çokakli M, Berk AT, Yaman A, Yesilirmak D, Kumral A, Atabey N. Associations of VEGF/VEGF-receptor and HGF/c-Met promoter polymorphisms with progression/regression of retinopathy of prematurity. Curr Eye Res 2013;38:137-42. [PMID: 23094709 DOI: 10.3109/02713683.2012.731550] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
7 Fabian KL, Storkus WJ. Immunotherapeutic Targeting of Tumor-Associated Blood Vessels. Adv Exp Med Biol 2017;1036:191-211. [PMID: 29275473 DOI: 10.1007/978-3-319-67577-0_13] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
8 Zhao W, Han Q, Lin H, Gao Y, Sun W, Zhao Y, Wang B, Chen B, Xiao Z, Dai J. Improved neovascularization and wound repair by targeting human basic fibroblast growth factor (bFGF) to fibrin. J Mol Med 2008;86:1127-38. [DOI: 10.1007/s00109-008-0372-9] [Cited by in Crossref: 40] [Cited by in F6Publishing: 33] [Article Influence: 2.9] [Reference Citation Analysis]
9 Kim Y, Park T, Singh B, Maharjan S, Choi Y, Choung P, Arote RB, Cho C. Nanoparticle-mediated delivery of siRNA for effective lung cancer therapy. Nanomedicine 2015;10:1165-88. [DOI: 10.2217/nnm.14.214] [Cited by in Crossref: 31] [Cited by in F6Publishing: 25] [Article Influence: 4.4] [Reference Citation Analysis]
10 Tang JH, Zhao JH, Lu JW, Yan F, Qin JW, Xu B. Circulating levels of angiogenic cytokines in advanced breast cancer patients with system chemotherapy and their potential value in monitoring disease course. J Cancer Res Clin Oncol 2011;137:55-63. [PMID: 20221635 DOI: 10.1007/s00432-010-0859-y] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
11 Schiffelers RM, Storm G. ICS-283: a system for targeted intravenous delivery of siRNA. Expert Opin Drug Deliv 2006;3:445-54. [PMID: 16640503 DOI: 10.1517/17425247.3.3.445] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 0.9] [Reference Citation Analysis]
12 Faustino-Rocha AI, Silva A, Gabriel J, Gil da Costa RM, Moutinho M, Oliveira PA, Gama A, Ferreira R, Ginja M. Long-term exercise training as a modulator of mammary cancer vascularization. Biomed Pharmacother 2016;81:273-80. [PMID: 27261604 DOI: 10.1016/j.biopha.2016.04.030] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 3.7] [Reference Citation Analysis]
13 Laham AJ, Saber-Ayad M, El-Awady R. DYRK1A: a down syndrome-related dual protein kinase with a versatile role in tumorigenesis. Cell Mol Life Sci 2021;78:603-19. [PMID: 32870330 DOI: 10.1007/s00018-020-03626-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
14 Hespanhol VP. Tratamento do cancro do pulmão – Decisão baseada na biologia, do gene à histologia. Revista Portuguesa de Pneumologia 2008;14:S27-34. [DOI: 10.1016/s0873-2159(15)30312-3] [Cited by in Crossref: 2] [Article Influence: 0.1] [Reference Citation Analysis]
15 Braghiroli MI, Sabbaga J, Hoff PM. Bevacizumab: overview of the literature. Expert Rev Anticancer Ther. 2012;12:567-580. [PMID: 22594892 DOI: 10.1586/era.12.13] [Cited by in Crossref: 55] [Cited by in F6Publishing: 51] [Article Influence: 5.5] [Reference Citation Analysis]
16 Yucel MA, Kurnaz IA. An in silico model for HIF-alpha regulation and hypoxia response in tumor cells. Biotechnol Bioeng 2007;97:588-600. [PMID: 17089387 DOI: 10.1002/bit.21247] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 0.7] [Reference Citation Analysis]
17 Bicknell R. Targeting angiogenesis with monoclonal antibodies. Ann Oncol 2006;17 Suppl 10:x76-8. [PMID: 17018756 DOI: 10.1093/annonc/mdl241] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
18 Clément-duchêne C, Wakelee H. Antiangiogenic Agents and Vascular Disrupting Agents for the Treatment of Lung Cancer: A Review. Journal of Thoracic Oncology 2010;5:129-39. [DOI: 10.1097/jto.0b013e3181c59a60] [Cited by in Crossref: 11] [Cited by in F6Publishing: 2] [Article Influence: 0.9] [Reference Citation Analysis]
19 Liu X, Zheng Q, Yu Q, Hu Y, Cheng Y, Shao Z, Chen L, Ding W, Gao D. Apatinib regulates the growth of gastric cancer cells by modulating apoptosis and autophagy. Naunyn-Schmiedeberg's Arch Pharmacol 2021;394:1009-18. [DOI: 10.1007/s00210-020-02018-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
20 Amorim RL, Pinczowski P, Neto RT, Rahal SC. Immunohistochemical evaluation of prostaglandin E2 and vascular endothelial growth factor in canine cutaneous mast cell tumours. Vet Comp Oncol 2010;8:23-7. [PMID: 20230578 DOI: 10.1111/j.1476-5829.2009.00202.x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
21 Pereira RC, Soares DC, Oliveira DC, de Sousa GF, Vieira-filho SA, Mercadante-simões MO, Lula I, Silva-cunha A, Duarte LP. Triterpenes from leaves of Cheiloclinium cognatum and their in vivo antiangiogenic activity. Magn Reson Chem 2018;56:360-6. [DOI: 10.1002/mrc.4716] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
22 García-Romero N, Palacín-Aliana I, Madurga R, Carrión-Navarro J, Esteban-Rubio S, Jiménez B, Collazo A, Pérez-Rodríguez F, Ortiz de Mendivil A, Fernández-Carballal C, García-Duque S, Diamantopoulos-Fernández J, Belda-Iniesta C, Prat-Acín R, Sánchez-Gómez P, Calvo E, Ayuso-Sacido A. Bevacizumab dose adjustment to improve clinical outcomes of glioblastoma. BMC Med 2020;18:142. [PMID: 32564774 DOI: 10.1186/s12916-020-01610-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
23 Gabriel EM, Fisher DT, Evans S, Takabe K, Skitzki JJ. Intravital microscopy in the study of the tumor microenvironment: from bench to human application. Oncotarget 2018;9:20165-78. [PMID: 29732011 DOI: 10.18632/oncotarget.24957] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 5.0] [Reference Citation Analysis]
24 Dvashi Z, Sar Shalom H, Shohat M, Ben-Meir D, Ferber S, Satchi-Fainaro R, Ashery-Padan R, Rosner M, Solomon AS, Lavi S. Protein phosphatase magnesium dependent 1A governs the wound healing-inflammation-angiogenesis cross talk on injury. Am J Pathol 2014;184:2936-50. [PMID: 25196308 DOI: 10.1016/j.ajpath.2014.07.022] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.6] [Reference Citation Analysis]
25 Chao WR, Amin K, Shi Y, Hobbs P, Tanabe M, Tanga M, Jong L, Collins N, Peters R, Laderoute K, Dinh D, Yean D, Hou C, Sato B, Alt C, Sambucetti L. SR16388: a steroidal antiangiogenic agent with potent inhibitory effect on tumor growth in vivo. Angiogenesis 2011;14:1-16. [PMID: 21104121 DOI: 10.1007/s10456-010-9191-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.3] [Reference Citation Analysis]
26 Ishdorj G, Johnston JB, Gibson SB. Cucurbitacin-I (JSI-124) activates the JNK/c-Jun signaling pathway independent of apoptosis and cell cycle arrest in B leukemic cells. BMC Cancer 2011;11:268. [PMID: 21702955 DOI: 10.1186/1471-2407-11-268] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 1.8] [Reference Citation Analysis]
27 Jain RK, Duda DG, Clark JW, Loeffler JS. Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat Clin Pract Oncol. 2006;3:24-40. [PMID: 16407877 DOI: 10.1038/ncponc0403] [Cited by in Crossref: 771] [Cited by in F6Publishing: 668] [Article Influence: 48.2] [Reference Citation Analysis]
28 Scagliotti GV. Potential role of multi-targeted tyrosine kinase inhibitors in non-small-cell lung cancer. Ann Oncol 2007;18 Suppl 10:x32-41. [PMID: 17761722 DOI: 10.1093/annonc/mdm412] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 0.9] [Reference Citation Analysis]
29 Siclari VA, Guise TA, Chirgwin JM. Breast cancer secreted factors alter the bone microenvironment. In: Mansel RE, Fodstad O, Jiang WG, editors. Metastasis of Breast Cancer. Dordrecht: Springer Netherlands; 2007. pp. 241-58. [DOI: 10.1007/978-1-4020-5867-7_12] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
30 Lin Y, Zhai E, Liao B, Xu L, Zhang X, Peng S, He Y, Cai S, Zeng Z, Chen M. Autocrine VEGF signaling promotes cell proliferation through a PLC-dependent pathway and modulates Apatinib treatment efficacy in gastric cancer. Oncotarget 2017;8:11990-2002. [PMID: 28061477 DOI: 10.18632/oncotarget.14467] [Cited by in Crossref: 31] [Cited by in F6Publishing: 32] [Article Influence: 6.2] [Reference Citation Analysis]
31 Sakurai K, Yamada N, Yashiro M, Matsuzaki T, Komatsu M, Ohira M, Miwa A, Hirakawa K. A novel angiogenesis inhibitor, Ki23057, is useful for preventing the progression of colon cancer and the spreading of cancer cells to the liver. Eur J Cancer 2007;43:2612-20. [PMID: 17949968 DOI: 10.1016/j.ejca.2007.09.002] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
32 Geng Q, Shen H, Zhu W, Lu Y, Wang M, Jiang H, Li D. Safety and Efficacy of Low-Dosage Apatinib Monotherapy in Advanced Lung Squamous-Cell Carcinoma: A Prospective Cohort Study. Onco Targets Ther 2020;13:11529-35. [PMID: 33204107 DOI: 10.2147/OTT.S277532] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
33 Leong H, Mathur PS, Greene GL. Green tea catechins inhibit angiogenesis through suppression of STAT3 activation. Breast Cancer Res Treat. 2009;117:505-515. [PMID: 18821062 DOI: 10.1007/s10549-008-0196-x] [Cited by in Crossref: 43] [Cited by in F6Publishing: 38] [Article Influence: 3.1] [Reference Citation Analysis]
34 Fan M, Zhang J, Wang Z, Wang B, Zhang Q, Zheng C, Li T, Ni C, Wu Z, Shao Z. Phosphorylated VEGFR2 and hypertension: potential biomarkers to indicate VEGF-dependency of advanced breast cancer in anti-angiogenic therapy. Breast Cancer Res Treat. 2014;143:141-151. [PMID: 24292957 DOI: 10.1007/s10549-013-2793-6] [Cited by in Crossref: 37] [Cited by in F6Publishing: 46] [Article Influence: 4.1] [Reference Citation Analysis]
35 Dong Z, Zeitlin BD, Song W, Sun Q, Karl E, Spencer DM, Jain HV, Jackson T, Núñez G, Nör JE. Level of endothelial cell apoptosis required for a significant decrease in microvessel density. Exp Cell Res 2007;313:3645-57. [PMID: 17720154 DOI: 10.1016/j.yexcr.2007.07.023] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 1.1] [Reference Citation Analysis]
36 Bruce D, Tan PH. Vascular endothelial growth factor receptors and the therapeutic targeting of angiogenesis in cancer: where do we go from here? Cell Commun Adhes 2011;18:85-103. [PMID: 22017472 DOI: 10.3109/15419061.2011.619673] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 1.7] [Reference Citation Analysis]
37 Grau SJ, Trillsch F, Herms J, Thon N, Nelson PJ, Tonn JC, Goldbrunner R. Expression of VEGFR3 in glioma endothelium correlates with tumor grade. J Neurooncol 2007;82:141-50. [PMID: 17115285 DOI: 10.1007/s11060-006-9272-4] [Cited by in Crossref: 43] [Cited by in F6Publishing: 40] [Article Influence: 2.7] [Reference Citation Analysis]
38 Mo XD, Xu LP, Liu DH, Zhang XH, Chen H, Chen YH, Han W, Wang Y, Wang FR, Wang JZ, Liu KY, Huang XJ. The hematopoietic cell transplantation-specific comorbidity index (HCT-CI) is an outcome predictor for partially matched related donor transplantation. Am J Hematol 2013;88:497-502. [PMID: 23536204 DOI: 10.1002/ajh.23443] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 2.8] [Reference Citation Analysis]
39 Glade Bender J, Yamashiro DJ, Fox E. Clinical development of VEGF signaling pathway inhibitors in childhood solid tumors. Oncologist 2011;16:1614-25. [PMID: 22042784 DOI: 10.1634/theoncologist.2011-0148] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
40 Haddad RI, Schlumberger M, Wirth LJ, Sherman EJ, Shah MH, Robinson B, Dutcus CE, Teng A, Gianoukakis AG, Sherman SI. Incidence and timing of common adverse events in Lenvatinib-treated patients from the SELECT trial and their association with survival outcomes. Endocrine 2017;56:121-8. [PMID: 28155175 DOI: 10.1007/s12020-017-1233-5] [Cited by in Crossref: 46] [Cited by in F6Publishing: 41] [Article Influence: 9.2] [Reference Citation Analysis]
41 Zhao J, Zhao L, Chen W, He L, Li X. Taspine downregulates VEGF expression and inhibits proliferation of vascular endothelial cells through PI3 kinase and MAP kinase signaling pathways. Biomedicine & Pharmacotherapy 2008;62:383-9. [DOI: 10.1016/j.biopha.2007.07.013] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
42 Kise K, Kinugasa-Katayama Y, Takakura N. Tumor microenvironment for cancer stem cells. Adv Drug Deliv Rev. 2016;99:197-205. [PMID: 26362921 DOI: 10.1016/j.addr.2015.08.005] [Cited by in Crossref: 90] [Cited by in F6Publishing: 86] [Article Influence: 12.9] [Reference Citation Analysis]
43 Ashrafian H, Ahmed K, Rowland SP, Patel VM, Gooderham NJ, Holmes E, Darzi A, Athanasiou T. Metabolic surgery and cancer: protective effects of bariatric procedures. Cancer 2011;117:1788-99. [PMID: 21509756 DOI: 10.1002/cncr.25738] [Cited by in Crossref: 107] [Cited by in F6Publishing: 83] [Article Influence: 8.9] [Reference Citation Analysis]
44 Cammarota R, Bertolini V, Pennesi G, Bucci EO, Gottardi O, Garlanda C, Laghi L, Barberis MC, Sessa F, Noonan DM. The tumor microenvironment of colorectal cancer: stromal TLR-4 expression as a potential prognostic marker. J Transl Med. 2010;8:112. [PMID: 21059221 DOI: 10.1186/1479-5876-8-112] [Cited by in Crossref: 93] [Cited by in F6Publishing: 91] [Article Influence: 7.8] [Reference Citation Analysis]
45 Dass CR, Tran TM, Choong PF. Angiogenesis inhibitors and the need for anti-angiogenic therapeutics. J Dent Res 2007;86:927-36. [PMID: 17890668 DOI: 10.1177/154405910708601005] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 1.5] [Reference Citation Analysis]
46 Gong Z, Ma J, Su H, Guo T, Cai H, Chen Q, Zhao X, Qi J, Du J. Interleukin-1 receptor antagonist inhibits angiogenesis in gastric cancer. Int J Clin Oncol 2018;23:659-70. [PMID: 29344744 DOI: 10.1007/s10147-018-1242-2] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
47 Chen XM, Ye L, Leng AM, Liu T. Combined gene therapy system pcDNA 3.1(-)-shVEGF/yCDglyTK inhibits proliferation of gastric cancer cells. Shijie Huaren Xiaohua Zazhi 2013; 21(21): 2063-2069 [DOI: 10.11569/wcjd.v21.i21.2063] [Reference Citation Analysis]
48 Tremolada G, Lattanzio R, Mazzolari G, Zerbini G. The therapeutic potential of VEGF inhibition in diabetic microvascular complications. Am J Cardiovasc Drugs 2007;7:393-8. [PMID: 18076206 DOI: 10.2165/00129784-200707060-00002] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 1.3] [Reference Citation Analysis]
49 Aksoy S, Aksoy H, Harputluoglu H, Kilickap S, Altundag K. Treatment of comorbidities besides the treatment of primary tumor may further increase effective management of cancer. Medical Hypotheses 2006;67:744-6. [DOI: 10.1016/j.mehy.2006.04.033] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
50 Rosen LS, Ashurst HL, Chap L. Targeting signal transduction pathways in metastatic breast cancer: a comprehensive review. Oncologist 2010;15:216-35. [PMID: 20200040 DOI: 10.1634/theoncologist.2009-0145] [Cited by in Crossref: 33] [Cited by in F6Publishing: 25] [Article Influence: 2.8] [Reference Citation Analysis]
51 Sofou S. Radionuclide carriers for targeting of cancer. Int J Nanomedicine 2008;3:181-99. [PMID: 18686778 DOI: 10.2147/ijn.s2736] [Cited by in Crossref: 60] [Cited by in F6Publishing: 25] [Article Influence: 4.3] [Reference Citation Analysis]
52 Pang R, Tse E, Poon RT. Molecular pathways in hepatocellular carcinoma. Cancer Lett. 2006;240:157-169. [PMID: 16239065 DOI: 10.1016/j.canlet.2005.08.031] [Cited by in Crossref: 62] [Cited by in F6Publishing: 63] [Article Influence: 3.6] [Reference Citation Analysis]
53 Sun S, Schiller JH. Angiogenesis inhibitors in the treatment of lung cancer. Crit Rev Oncol Hematol 2007;62:93-104. [PMID: 17306557 DOI: 10.1016/j.critrevonc.2007.01.002] [Cited by in Crossref: 32] [Cited by in F6Publishing: 26] [Article Influence: 2.1] [Reference Citation Analysis]
54 Wheatley-price P, Shepherd FA. Targeting Angiogenesis in the Treatment of Lung Cancer. Journal of Thoracic Oncology 2008;3:1173-84. [DOI: 10.1097/jto.0b013e318187220f] [Cited by in Crossref: 32] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
55 Mitchell SA, Danca MD, Blomgren PA, Darrow JW, Currie KS, Kropf JE, Lee SH, Gallion SL, Xiong JM, Pippin DA, DeSimone RW, Brittelli DR, Eustice DC, Bourret A, Hill-Drzewi M, Maciejewski PM, Elkin LL. Imidazo[1,2-a]pyrazine diaryl ureas: inhibitors of the receptor tyrosine kinase EphB4. Bioorg Med Chem Lett 2009;19:6991-5. [PMID: 19879134 DOI: 10.1016/j.bmcl.2009.10.037] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 1.9] [Reference Citation Analysis]
56 Ko YH, Jung CK, Oh SN, Kim TH, Won HS, Kang JH, Kim HJ, Kang WK, Oh ST, Hong YS. Primary signet ring cell carcinoma of the appendix: A rare case report and our 18-year experience. World J Gastroenterol 2008; 14(37): 5763-5768 [PMID: 18837098 DOI: 10.3748/wjg.14.5763] [Cited by in CrossRef: 24] [Cited by in F6Publishing: 15] [Article Influence: 1.7] [Reference Citation Analysis]
57 Brito LG, Schiavon VF, Andrade JM, Tiezzi DG, Peria FM, Marana HR. Expression of Hypoxia-inducible factor 1-α and vascular endothelial growth factor-C in locally advanced breast cancer patients. Clinics (Sao Paulo) 2011;66:1313-20. [PMID: 21915477 DOI: 10.1590/s1807-59322011000800002] [Cited by in F6Publishing: 9] [Reference Citation Analysis]
58 Patel N, Moenkemeyer F, Germano S, Cheung MMH. Plasma vascular endothelial growth factor A and placental growth factor: novel biomarkers of pulmonary hypertension in congenital diaphragmatic hernia. American Journal of Physiology-Lung Cellular and Molecular Physiology 2015;308:L378-83. [DOI: 10.1152/ajplung.00261.2014] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 2.1] [Reference Citation Analysis]
59 Braghiroli MI, Riechelmann RP, Sabbaga J, Hoff PM. Do We Need another Antiangiogenesis Agent for Colorectal Cancer: are Bevacizumab and Aflibercept the Same? Curr Colorectal Cancer Rep 2013;9:317-25. [DOI: 10.1007/s11888-013-0187-0] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
60 Pal K, Madamsetty VS, Dutta SK, Wang E, Angom RS, Mukhopadhyay D. Synchronous inhibition of mTOR and VEGF/NRP1 axis impedes tumor growth and metastasis in renal cancer. NPJ Precis Oncol 2019;3:31. [PMID: 31840081 DOI: 10.1038/s41698-019-0105-2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
61 Hacking SM, Chakraborty B, Nasim R, Vitkovski T, Thomas R. A Holistic Appraisal of Stromal Differentiation in Colorectal Cancer: Biology, Histopathology, Computation, and Genomics. Pathol Res Pract 2021;220:153378. [PMID: 33690050 DOI: 10.1016/j.prp.2021.153378] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
62 Duda DG. Molecular Biomarkers of Response to Antiangiogenic Therapy for Cancer. ISRN Cell Biol 2012;2012:587259. [PMID: 24340224 DOI: 10.5402/2012/587259] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
63 Smith PW, Denlinger CE, Jones DR. Novel targeted therapies for non-small cell lung cancer. Thorac Surg Clin 2006;16:353-66. [PMID: 17240823 DOI: 10.1016/j.thorsurg.2006.09.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
64 Rao XM, Zheng X, Waigel S, Zacharias W, McMasters KM, Zhou HS. Gene expression profiles of normal human lung cells affected by adenoviral E1B. Virology 2006;350:418-28. [PMID: 16542696 DOI: 10.1016/j.virol.2006.02.009] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 1.2] [Reference Citation Analysis]
65 Trarbach T, Schultheis B, Gauler TC, Schneider V, Strumberg D, Eberhardt WEE, Le Scouiller S, Marotti M, Brown KH, Drevs J. Phase I open-label study of cediranib, an oral inhibitor of VEGF signalling, in combination with the oral Src inhibitor saracatinib in patients with advanced solid tumours. Invest New Drugs 2012;30:1962-71. [DOI: 10.1007/s10637-011-9754-x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
66 Kzhyshkowska J, Larionova I, Liu T. YKL-39 as a Potential New Target for Anti-Angiogenic Therapy in Cancer. Front Immunol 2019;10:2930. [PMID: 32038607 DOI: 10.3389/fimmu.2019.02930] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
67 Shih T, Lindley C. Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies. Clin Ther. 2006;28:1779-1802. [PMID: 17212999 DOI: 10.1016/j.clinthera.2006.11.015] [Cited by in Crossref: 343] [Cited by in F6Publishing: 291] [Article Influence: 22.9] [Reference Citation Analysis]
68 George DJ, Moore C. Angiogenesis inhibitors in clinical oncology. Update on Cancer Therapeutics 2006;1:429-34. [DOI: 10.1016/j.uct.2006.08.006] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
69 Lv W, Zhang C, Guo H, Liu W, Hao YX. Suppression of HCT116 cell proliferation by silencing vascular endothelial growth factor gene with RNA interference. Shijie Huaren Xiaohua Zazhi 2005; 13(24): 2870-2873 [DOI: 10.11569/wcjd.v13.i24.2870] [Reference Citation Analysis]
70 Musumeci F, Radi M, Brullo C, Schenone S. Vascular endothelial growth factor (VEGF) receptors: drugs and new inhibitors. J Med Chem 2012;55:10797-822. [PMID: 23098265 DOI: 10.1021/jm301085w] [Cited by in Crossref: 111] [Cited by in F6Publishing: 93] [Article Influence: 11.1] [Reference Citation Analysis]
71 Raval SH, Singh RD, Joshi DV, Patel HB, Mody SK. Recent developments in receptor tyrosine kinases targeted anticancer therapy. Vet World 2016;9:80-90. [PMID: 27051190 DOI: 10.14202/vetworld.2016.80-90] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
72 Srivastava S, Zahra FT, Gupta N, Tullar PE, Srivastava SK, Mikelis CM. Low Dose of Penfluridol Inhibits VEGF-Induced Angiogenesis. Int J Mol Sci 2020;21:E755. [PMID: 31979394 DOI: 10.3390/ijms21030755] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
73 Caine GJ, Lip G, Zanetto U, Maheshwari M, Stonelake PS, Blann AD. A comparison of plasma versus histologic indices of angiogenic markers in breast cancer. Appl Immunohistochem Mol Morphol 2007;15:382-8. [PMID: 18091379 DOI: 10.1097/01.pai.0000213137.01536.ca] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
74 Steurer M, Zoller H, Augustin F, Fong D, Heiss S, Strasser-weippl K, Gastl G, Tzankov A. Increased angiogenesis in chronic idiopathic myelofibrosis: vascular endothelial growth factor as a prominent angiogenic factor. Human Pathology 2007;38:1057-64. [DOI: 10.1016/j.humpath.2006.12.011] [Cited by in Crossref: 26] [Cited by in F6Publishing: 28] [Article Influence: 1.7] [Reference Citation Analysis]
75 Spiridonova VA. Molecular recognition elements: DNA/RNA-aptamers to proteins. Biochem Mosc Suppl B Biomed Chem 2010;4:138-49. [PMID: 32288940 DOI: 10.1134/S1990750810020046] [Cited by in Crossref: 5] [Article Influence: 0.4] [Reference Citation Analysis]
76 Dhankhar R, Vyas SP, Jain AK, Arora S, Rath G, Goyal AK. Advances in novel drug delivery strategies for breast cancer therapy. Artif Cells Blood Substit Immobil Biotechnol 2010;38:230-49. [PMID: 20677900 DOI: 10.3109/10731199.2010.494578] [Cited by in Crossref: 45] [Cited by in F6Publishing: 40] [Article Influence: 4.1] [Reference Citation Analysis]
77 Di Bartolomeo M, Maggi C, Ricchini F, Pietrantonio F, Iacovelli R, de Braud F, Inno A. Bevacizumab treatment in the elderly patient with metastatic colorectal cancer. Clin Interv Aging 2015;10:127-33. [PMID: 25584021 DOI: 10.2147/CIA.S54675] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
78 Mok TS, Hsia TC, Tsai CM, Tsang K, Chang GC, Chang JW, Sirisinha T, Sriuranpong V, Thongprasert S, Chua DT, Moore N, Manegold C. Efficacy of bevacizumab with cisplatin and gemcitabine in Asian patients with advanced or recurrent non-squamous non-small cell lung cancer who have not received prior chemotherapy: a substudy of the Avastin in Lung trial. Asia Pac J Clin Oncol 2011;7 Suppl 2:4-12. [PMID: 21585703 DOI: 10.1111/j.1743-7563.2011.01397.x] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 2.2] [Reference Citation Analysis]
79 Di Bartolomeo M, Pietrantonio F, Martinetti A, Buzzoni R, Gevorgyan A, Bajetta E. Role of the antiangiogenic agent bevacizumab in the treatment of elderly patients with metastatic colorectal cancer. Drugs Aging 2011;28:83-91. [PMID: 21155618 DOI: 10.2165/11584710-000000000-00000] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
80 Thorne SH, Tam BY, Kirn DH, Contag CH, Kuo CJ. Selective intratumoral amplification of an antiangiogenic vector by an oncolytic virus produces enhanced antivascular and anti-tumor efficacy. Mol Ther 2006;13:938-46. [PMID: 16469543 DOI: 10.1016/j.ymthe.2005.12.010] [Cited by in Crossref: 37] [Cited by in F6Publishing: 38] [Article Influence: 2.3] [Reference Citation Analysis]
81 Jun HY, Yin HH, Kim SH, Park SH, Kim HS, Yoon KH. Visualization of tumor angiogenesis using MR imaging contrast agent Gd-DTPA-anti-VEGF receptor 2 antibody conjugate in a mouse tumor model. Korean J Radiol 2010;11:449-56. [PMID: 20592929 DOI: 10.3348/kjr.2010.11.4.449] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
82 Nishimura T, Furihata M, Kubo H, Tani M, Agawa S, Setoyama R, Toyoda T. Intracranial hemorrhage in patients treated with bevacizumab: Report of two cases. World J Gastroenterol 2011; 17(39): 4440-4444 [PMID: 22110272 DOI: 10.3748/wjg.v17.i39.4440] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
83 Camacho X, García MF, Calzada V, Fernández M, Chabalgoity JA, Moreno M, Barbosa de Aguiar R, Alonso O, Gambini JP, Chammas R, Cabral P. [(99m)Tc(CO)(3)]-radiolabeled bevacizumab: in vitro and in vivo evaluation in a melanoma model. Oncology 2013;84:200-9. [PMID: 23328435 DOI: 10.1159/000338961] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
84 Crowe A, Jackaman C, Beddoes KM, Ricciardo B, Nelson DJ. Rapid copper acquisition by developing murine mesothelioma: decreasing bioavailable copper slows tumor growth, normalizes vessels and promotes T cell infiltration. PLoS One 2013;8:e73684. [PMID: 24013775 DOI: 10.1371/journal.pone.0073684] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 2.1] [Reference Citation Analysis]
85 Rahimi N. Vascular endothelial growth factor receptors: molecular mechanisms of activation and therapeutic potentials. Exp Eye Res 2006;83:1005-16. [PMID: 16713597 DOI: 10.1016/j.exer.2006.03.019] [Cited by in Crossref: 54] [Cited by in F6Publishing: 56] [Article Influence: 3.4] [Reference Citation Analysis]
86 Filippello A, Porcheron J, Klein JP, Cottier M, Barabino G. Affinity of indocyanine green in the detection of colorectal peritoneal carcinomatosis. Surg Innov. 2017;24:103-108. [PMID: 27909239 DOI: 10.1177/1553350616681897] [Cited by in Crossref: 11] [Cited by in F6Publishing: 15] [Article Influence: 1.8] [Reference Citation Analysis]
87 Takahashi Y, Iwamoto T, Suzuki Y, Kajiwara Y, Hatono M, Tsukioki T, Kawada K, Kochi M, Ikeda H, Shien T, Taira N, Matsuoka J, Doihara H, Toyooka S. Evaluation of Therapeutic Target Gene Expression Based on Residual Cancer Burden Classification After Neoadjuvant Chemotherapy for HER2-Negative Breast Cancer. Clin Breast Cancer 2020;20:117-124.e4. [PMID: 31570267 DOI: 10.1016/j.clbc.2019.07.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
88 Wang Q, Sun L, Yan J, Wang S, Zhang J, Zheng X. Expression of vascular endothelial growth factor and caspase-3 in mucinous breast carcinoma and infiltrating ductal carcinoma-not otherwise specified, and the correlation with disease-free survival. Oncol Lett 2017;14:4890-6. [PMID: 29085497 DOI: 10.3892/ol.2017.6744] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
89 Zhang WJ, Lu SY. Advances in molecularly targeted therapy of hepatocellular carcinoma. Shijie Huaren Xiaohua Zazhi 2011; 19(4): 331-337 [DOI: 10.11569/wcjd.v19.i4.331] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
90 Eton DT, Yost KJ, Cella D. Future trends in patient-reported outcomes assessment for patients with advanced-stage lung cancer receiving targeted therapy. Clin Lung Cancer 2006;8:99-109. [PMID: 17026810 DOI: 10.3816/CLC.2006.n.037] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
91 Martano M, Restucci B, Ceccarelli DM, Lo Muzio L, Maiolino P. Immunohistochemical expression of vascular endothelial growth factor in canine oral squamous cell carcinomas. Oncol Lett 2016;11:399-404. [PMID: 26870224 DOI: 10.3892/ol.2015.3847] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]